Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 9/2012

01.09.2012 | Original Article

Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI

verfasst von: Ali Afshar-Oromieh, Frederik L. Giesel, Heinz G. Linhart, Uwe Haberkorn, Sabine Haufe, Stephanie E. Combs, Dino Podlesek, Michael Eisenhut, Clemens Kratochwil

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

PET imaging with somatostatin receptor ligands, such as 68Ga-DOTATOC, is a well-established method for detection and target volume definition of meningiomas prior to radiotherapy. Since DOTATOC PET delivers a higher contrast between meningiomas and surrounding tissues than MRI, we conducted a retrospective analysis to compare the diagnostic accuracy of contrast-enhanced MRI (CE-MRI) with 68Ga-DOTATOC PET/CT in patients with cranial meningiomas prior to radiotherapy.

Methods

Over a period of 6 years, 134 patients (20–82 years of age, 107 women and 27 men) underwent cranial CE-MRI and 68Ga-DOTATOC PET/CT. To compare the two methods, the lesions considered typical of meningiomas visually were counted and analysed with respect to their location and SUVmax.

Results

In the 134 patients investigated by both modalities, 190 meningiomas were detected by 68Ga-DOTATOC PET/CT and 171 by CE-MRI. With knowledge of the PET/CT data, the MRI scans were reinvestigated, which led to the detection of 4 of the 19 incidental meningiomas, resulting in an overall detection rate of 92 % of the meningioma lesions that were found by PET/CT.

Conclusion

Ga-DOTATOC PET/CT demonstrated an improved sensitivity in meningioma detection when compared to CE-MRI. Tumours adjacent to the falx cerebri, located at the skull base or obscured by imaging artefacts or calcification are particularly difficult to detect by MRI. Therefore 68Ga-DOTATOC PET/CT may provide additional information in patients with uncertain or equivocal results on MRI or could help to confirm a diagnosis of meningioma based on MRI or could help to confirm MRI-based diagnosis of meningiomas in cases of biopsy limitations. It is possible that not only radiotherapy and surgical planning, but also follow-up strategies would benefit from this imaging modality.
Literatur
1.
Zurück zum Zitat Black P. Meningiomas. In: Black P, Loeffler JS, editors. Cancer of the nervous system. Oxford, UK: Blackwell Science; 1997. p. 349–62. Black P. Meningiomas. In: Black P, Loeffler JS, editors. Cancer of the nervous system. Oxford, UK: Blackwell Science; 1997. p. 349–62.
2.
Zurück zum Zitat Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985;62:18–24.PubMedCrossRef Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985;62:18–24.PubMedCrossRef
3.
Zurück zum Zitat De Jesús O, Sekhar LN, Parikh HK, Wright DC, Wagner DP. Long-term follow-up of patients with meningioma involving the cavernous sinus. Recurrence, progression and quality of life. Neurosurgery. 1996;39:915–9.PubMedCrossRef De Jesús O, Sekhar LN, Parikh HK, Wright DC, Wagner DP. Long-term follow-up of patients with meningioma involving the cavernous sinus. Recurrence, progression and quality of life. Neurosurgery. 1996;39:915–9.PubMedCrossRef
4.
Zurück zum Zitat Mathiesen T, Lindquist C, Kihlstrom L, Karlsson B. Recurrence of cranial base meningiomas. Neurosurgery. 1996;39:2–7.PubMedCrossRef Mathiesen T, Lindquist C, Kihlstrom L, Karlsson B. Recurrence of cranial base meningiomas. Neurosurgery. 1996;39:2–7.PubMedCrossRef
5.
Zurück zum Zitat Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc. 1998;73:936–42.PubMedCrossRef Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc. 1998;73:936–42.PubMedCrossRef
6.
Zurück zum Zitat Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med. 2001;42:1053–6.PubMed Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med. 2001;42:1053–6.PubMed
7.
Zurück zum Zitat Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46:763–9.PubMed Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46:763–9.PubMed
8.
Zurück zum Zitat Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65(1):222–7.PubMedCrossRef Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65(1):222–7.PubMedCrossRef
9.
Zurück zum Zitat Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, et al. Comparison of (68)Ga-DOTATOC PET and (111)In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617–26.PubMedCrossRef Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, et al. Comparison of (68)Ga-DOTATOC PET and (111)In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617–26.PubMedCrossRef
10.
Zurück zum Zitat Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med. 1997;24:792–5.PubMed Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med. 1997;24:792–5.PubMed
11.
Zurück zum Zitat Gehler B, Paulsen F, Oksüz MO, Hauser TK, Eschmann SM, Bares R, et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009;4:56.PubMedCrossRef Gehler B, Paulsen F, Oksüz MO, Hauser TK, Eschmann SM, Bares R, et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009;4:56.PubMedCrossRef
12.
Zurück zum Zitat Brix G, Bellemann ME, Hauser H, Doll J. Recovery coefficients for the quantification of the arterial input functions from dynamic PET measurements: experimental and theoretical determination. Nuklearmedizin. 2002;41:184–90.PubMed Brix G, Bellemann ME, Hauser H, Doll J. Recovery coefficients for the quantification of the arterial input functions from dynamic PET measurements: experimental and theoretical determination. Nuklearmedizin. 2002;41:184–90.PubMed
13.
Zurück zum Zitat Rostomily RC, Elias M, Deng M, Elias P, Born DE, Muballe D, et al. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. Head Neck. 2006;28:305–12.PubMedCrossRef Rostomily RC, Elias M, Deng M, Elias P, Born DE, Muballe D, et al. Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. Head Neck. 2006;28:305–12.PubMedCrossRef
14.
Zurück zum Zitat Pasquali D, Notaro A, Bonavolonta’ G, Vassallo P, Bellastella A, Sinisi AA. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves’ disease. J Clin Endocrinol Metab. 2002;87:5125–9.PubMedCrossRef Pasquali D, Notaro A, Bonavolonta’ G, Vassallo P, Bellastella A, Sinisi AA. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves’ disease. J Clin Endocrinol Metab. 2002;87:5125–9.PubMedCrossRef
15.
Zurück zum Zitat Scheidhauer K, Hildebrandt G, Luyken C, Schomäcker K, Klug N, Schicha H. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences. Horm Metab Res Suppl. 1993;27:59–62.PubMed Scheidhauer K, Hildebrandt G, Luyken C, Schomäcker K, Klug N, Schicha H. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences. Horm Metab Res Suppl. 1993;27:59–62.PubMed
16.
Zurück zum Zitat Chen CC, Czerwiec FS, Feuillan PP. Visualization of fibrous dysplasia during somatostatin receptor scintigraphy. J Nucl Med. 1998;39:238–40.PubMed Chen CC, Czerwiec FS, Feuillan PP. Visualization of fibrous dysplasia during somatostatin receptor scintigraphy. J Nucl Med. 1998;39:238–40.PubMed
17.
Zurück zum Zitat Kang S, Mishkin FS. Visualization of Paget’s disease during somatostatin receptor scintigraphy. Clin Nucl Med. 1999;24:900–2.PubMedCrossRef Kang S, Mishkin FS. Visualization of Paget’s disease during somatostatin receptor scintigraphy. Clin Nucl Med. 1999;24:900–2.PubMedCrossRef
18.
Zurück zum Zitat Elgeti F, Amthauer H, Denecke T, Steffen I, Heuck F, Stelter L, et al. Incidental detection of breast cancer by 68Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours. Nuklearmedizin. 2008;47:261–5.PubMed Elgeti F, Amthauer H, Denecke T, Steffen I, Heuck F, Stelter L, et al. Incidental detection of breast cancer by 68Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours. Nuklearmedizin. 2008;47:261–5.PubMed
Metadaten
Titel
Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI
verfasst von
Ali Afshar-Oromieh
Frederik L. Giesel
Heinz G. Linhart
Uwe Haberkorn
Sabine Haufe
Stephanie E. Combs
Dino Podlesek
Michael Eisenhut
Clemens Kratochwil
Publikationsdatum
01.09.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-012-2155-3

Weitere Artikel der Ausgabe 9/2012

European Journal of Nuclear Medicine and Molecular Imaging 9/2012 Zur Ausgabe